NEW YORK, Feb. 20, 2026 — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology firm focused on improving patient results through the development of fast-acting, long-lasting and user-friendly mental health therapies, today announced it will hold a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The program will include presentations and live question-and-answer sessions with members of the Company’s executive leadership team and several external key opinion leaders.
Investors, analysts, and members of the media can sign up for the live webcast. A recording will be accessible following the event on the investor section of the AtaiBeckley website, under .
Registration Link:
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company focused on improving patient results through the development of fast-acting, long-lasting and user-friendly mental health therapies. AtaiBeckley’s portfolio of innovative treatments comprises BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is preparing for Phase 3 trials, VLS-01 and EMP-01 are currently in Phase 2 studies. The Company is also progressing a research initiative to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs seek to deliver innovations in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit or follow the Company on and on .
Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
Media:
Charlotte Chorley
Associate Director, Communications
